Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Year: 2017
Type: article
Study design: Clinical Trial
Abstract: Purpose: Patients with glioblastoma have less than 15-month median survival despite surgical resection, high-dose radiation, and chemotherapy with temozolomide. We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can extend survival and, in a separate study, that dose-intensified temozolomide (DI-TMZ) and adjuvant granulocyte macrophage colony-stimulating factor (GM-CSF) potentiate tumor-specific immune responses in patients with glioblastoma. Here, we evaluated pp65-specific cellular responses following DI-TMZ with pp65-DCs and determined the effects on long-term progression-free survival (PFS) and overall survival (OS). Experimental Design: Following standard-of-care, 11 patients with newly diagnosed glioblastoma received DI-TMZ (100 mg/m2/d × 21 days per cycle) with at least three vaccines of pp65 lysosome–associated membrane glycoprotein mRNA-pulsed DCs admixed with GM-CSF on day 23 ± 1 of each cycle. Thereafter, monthly DI-TMZ cycles and pp65-DCs were continued if patients had not progressed. Results: Following DI-TMZ cycle 1 and three doses of pp65-DCs, pp65 cellular responses significantly increased. After DI-TMZ, both the proportion and proliferation of regulatory T cells (Tregs) increased and remained elevated with serial DI-TMZ cycles. Median PFS and OS were 25.3 months [95% confidence interval (CI), 11.0–∞] and 41.1 months (95% CI, 21.6–∞), exceeding survival using recursive partitioning analysis and matched historical controls. Four patients remained progression-free at 59 to 64 months from diagnosis. No known prognostic factors [age, Karnofsky performance status (KPS), IDH-1/2 mutation, and MGMT promoter methylation] predicted more favorable outcomes for the patients in this cohort. Conclusions: Despite increased Treg proportions following DI-TMZ, patients receiving pp65-DCs showed long-term PFS and OS, confirming prior studies targeting cytomegalovirus in glioblastoma. Clin Cancer Res; 23(8); 1898–909. ©2017 AACR.
Source: Clinical Cancer Research
Authors: Kristen A. Batich, Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, Weihua Xie, James E. Herndon, Patrick Healy, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Darell Bigner, Gordana Vlahovic, Duane A. Mitchell, John H. Sampson
Institutions: Duke Medical Center, Duke University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Duke University, Israel National Road Safety Authority, National Institutes of Health, Small Business Innovative Research and Small Business Technology Transfer, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences
Awards: Together: Transforming and Translating Discovery to Improve Health, Medical Scientist Training Program, Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine), G3445316497, Reversal of CMV-specific Immune Deficits in Patients with Glioblastoma, Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors, G4014004988, Brain Tumor Targeting Using Tumor-Specific Neuroimmunology, NINDS Research Education Programs for Residents and Fellows in Neurosurgery, EGFRvIII-targeted Bispecific T cell Engagers for brain tumors, Duke SPORE in Brain Cancer, Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells, Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy, G6111380403, Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma, Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide, Enhancing dendritic cell migration to drive potent anti-tumor immune responses, G8640382938, G9000296386, Medical Scientist Training Program Training Grant, Cancer Center Support Grant (CCSG)
OpenAlex ID: W2606625852
